entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients
UF startup and UF Innovate | Sid Martin Biotech resident entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has secured $49 million in non-dilutive growth capital from Jefferies Group LLC’s subsidiary, Jefferies Funding LLC (Jefferies). The event follows Series A and B raises, including multiple rounds of investment from Johnson & Johnson INNOVATION | JJDC. Aon Plc’s Intellectual Property Solutions also played an important role in helping to secure key Collateral Protection Insurance to support the financing.
“Our platform represents a new modality for creating functional ingredients and active pharmaceutical ingredients (APIs) that are highly efficacious, safe, and cost-effective,” said EBS CEO Stephen Gatto. EBS is pioneering an innovative approach to protein and ion channel modulation that originated from a $40 million NASA|BARDA grant. “This financing greatly accelerates the numerous commercialization efforts already underway with leading OTC, CPG, and therapeutic companies.”
Learn more about entrinsic bioscience Secures $49 Million in Financing To Accelerate Development and Commercialization of Next Generation Functional Ingredients and Active Pharmaceutical Ingredients.